IBDEI0AU ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14469,1,8,0)
 ;;=8^Hx-Intrathoracic Mal Nec
 ;;^UTILITY(U,$J,358.3,14469,2)
 ;;=^295216
 ;;^UTILITY(U,$J,358.3,14470,0)
 ;;=V10.87^^87^786^12
 ;;^UTILITY(U,$J,358.3,14470,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14470,1,1,0)
 ;;=1^V10.87
 ;;^UTILITY(U,$J,358.3,14470,1,8,0)
 ;;=8^Hx Of Thyroid Malignancy
 ;;^UTILITY(U,$J,358.3,14470,2)
 ;;=^295245
 ;;^UTILITY(U,$J,358.3,14471,0)
 ;;=V10.51^^87^786^1
 ;;^UTILITY(U,$J,358.3,14471,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14471,1,1,0)
 ;;=1^V10.51
 ;;^UTILITY(U,$J,358.3,14471,1,8,0)
 ;;=8^Hx Of Bladder Malignancy
 ;;^UTILITY(U,$J,358.3,14471,2)
 ;;=^295228
 ;;^UTILITY(U,$J,358.3,14472,0)
 ;;=V10.52^^87^786^9
 ;;^UTILITY(U,$J,358.3,14472,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14472,1,1,0)
 ;;=1^V10.52
 ;;^UTILITY(U,$J,358.3,14472,1,8,0)
 ;;=8^Hx Of Kidney Malignancy
 ;;^UTILITY(U,$J,358.3,14472,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,14473,0)
 ;;=V10.46^^87^786^29
 ;;^UTILITY(U,$J,358.3,14473,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14473,1,1,0)
 ;;=1^V10.46
 ;;^UTILITY(U,$J,358.3,14473,1,8,0)
 ;;=8^Hx-Prostatic Malignancy
 ;;^UTILITY(U,$J,358.3,14473,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,14474,0)
 ;;=V10.47^^87^786^32
 ;;^UTILITY(U,$J,358.3,14474,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14474,1,1,0)
 ;;=1^V10.47
 ;;^UTILITY(U,$J,358.3,14474,1,8,0)
 ;;=8^Hx-Testicular Malignancy
 ;;^UTILITY(U,$J,358.3,14474,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,14475,0)
 ;;=V10.49^^87^786^23
 ;;^UTILITY(U,$J,358.3,14475,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14475,1,1,0)
 ;;=1^V10.49
 ;;^UTILITY(U,$J,358.3,14475,1,8,0)
 ;;=8^Hx-Male Genit Malig Nec
 ;;^UTILITY(U,$J,358.3,14475,2)
 ;;=^295226
 ;;^UTILITY(U,$J,358.3,14476,0)
 ;;=V10.45^^87^786^24
 ;;^UTILITY(U,$J,358.3,14476,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14476,1,1,0)
 ;;=1^V10.45
 ;;^UTILITY(U,$J,358.3,14476,1,8,0)
 ;;=8^Hx-Male Genit Malig Nos
 ;;^UTILITY(U,$J,358.3,14476,2)
 ;;=^295223
 ;;^UTILITY(U,$J,358.3,14477,0)
 ;;=V10.3^^87^786^4
 ;;^UTILITY(U,$J,358.3,14477,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14477,1,1,0)
 ;;=1^V10.3
 ;;^UTILITY(U,$J,358.3,14477,1,8,0)
 ;;=8^Hx Of Breast Malignancy
 ;;^UTILITY(U,$J,358.3,14477,2)
 ;;=^295217
 ;;^UTILITY(U,$J,358.3,14478,0)
 ;;=V10.41^^87^786^15
 ;;^UTILITY(U,$J,358.3,14478,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14478,1,1,0)
 ;;=1^V10.41
 ;;^UTILITY(U,$J,358.3,14478,1,8,0)
 ;;=8^Hx-Cervical Malignancy
 ;;^UTILITY(U,$J,358.3,14478,2)
 ;;=^295219
 ;;^UTILITY(U,$J,358.3,14479,0)
 ;;=V10.42^^87^786^34
 ;;^UTILITY(U,$J,358.3,14479,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14479,1,1,0)
 ;;=1^V10.42
 ;;^UTILITY(U,$J,358.3,14479,1,8,0)
 ;;=8^Hx-Uterus Malignancy Nec
 ;;^UTILITY(U,$J,358.3,14479,2)
 ;;=^295220
 ;;^UTILITY(U,$J,358.3,14480,0)
 ;;=V10.43^^87^786^11
 ;;^UTILITY(U,$J,358.3,14480,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14480,1,1,0)
 ;;=1^V10.43
 ;;^UTILITY(U,$J,358.3,14480,1,8,0)
 ;;=8^Hx Of Ovarian Malignancy
 ;;^UTILITY(U,$J,358.3,14480,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,14481,0)
 ;;=V10.44^^87^786^18
 ;;^UTILITY(U,$J,358.3,14481,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14481,1,1,0)
 ;;=1^V10.44
 ;;^UTILITY(U,$J,358.3,14481,1,8,0)
 ;;=8^Hx-Female Genit Malg Nec
 ;;^UTILITY(U,$J,358.3,14481,2)
 ;;=^295222
 ;;^UTILITY(U,$J,358.3,14482,0)
 ;;=V10.81^^87^786^2
 ;;^UTILITY(U,$J,358.3,14482,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14482,1,1,0)
 ;;=1^V10.81
 ;;^UTILITY(U,$J,358.3,14482,1,8,0)
 ;;=8^Hx Of Bone Malignancy
 ;;^UTILITY(U,$J,358.3,14482,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,14483,0)
 ;;=V10.82^^87^786^25
 ;;^UTILITY(U,$J,358.3,14483,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14483,1,1,0)
 ;;=1^V10.82
 ;;^UTILITY(U,$J,358.3,14483,1,8,0)
 ;;=8^Hx-Malig Skin Melanoma
 ;;^UTILITY(U,$J,358.3,14483,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,14484,0)
 ;;=V10.83^^87^786^31
 ;;^UTILITY(U,$J,358.3,14484,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14484,1,1,0)
 ;;=1^V10.83
 ;;^UTILITY(U,$J,358.3,14484,1,8,0)
 ;;=8^Hx-Skin Malignancy Nec
 ;;^UTILITY(U,$J,358.3,14484,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,14485,0)
 ;;=V10.84^^87^786^6
 ;;^UTILITY(U,$J,358.3,14485,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14485,1,1,0)
 ;;=1^V10.84
 ;;^UTILITY(U,$J,358.3,14485,1,8,0)
 ;;=8^Hx Of Eye Malignancy
 ;;^UTILITY(U,$J,358.3,14485,2)
 ;;=^295242
 ;;^UTILITY(U,$J,358.3,14486,0)
 ;;=V10.85^^87^786^3
 ;;^UTILITY(U,$J,358.3,14486,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14486,1,1,0)
 ;;=1^V10.85
 ;;^UTILITY(U,$J,358.3,14486,1,8,0)
 ;;=8^Hx Of Brain Malignancy
 ;;^UTILITY(U,$J,358.3,14486,2)
 ;;=^295243
 ;;^UTILITY(U,$J,358.3,14487,0)
 ;;=V10.86^^87^786^26
 ;;^UTILITY(U,$J,358.3,14487,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14487,1,1,0)
 ;;=1^V10.86
 ;;^UTILITY(U,$J,358.3,14487,1,8,0)
 ;;=8^Hx-Malign Nerve Syst Nec
 ;;^UTILITY(U,$J,358.3,14487,2)
 ;;=^295244
 ;;^UTILITY(U,$J,358.3,14488,0)
 ;;=V10.88^^87^786^16
 ;;^UTILITY(U,$J,358.3,14488,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14488,1,1,0)
 ;;=1^V10.88
 ;;^UTILITY(U,$J,358.3,14488,1,8,0)
 ;;=8^Hx-Endocrine Malign Nec
 ;;^UTILITY(U,$J,358.3,14488,2)
 ;;=^295246
 ;;^UTILITY(U,$J,358.3,14489,0)
 ;;=238.0^^87^787^1
 ;;^UTILITY(U,$J,358.3,14489,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14489,1,1,0)
 ;;=1^238.0
 ;;^UTILITY(U,$J,358.3,14489,1,8,0)
 ;;=8^Bone and Articular Cartilage
 ;;^UTILITY(U,$J,358.3,14489,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,14490,0)
 ;;=238.1^^87^787^3
 ;;^UTILITY(U,$J,358.3,14490,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14490,1,1,0)
 ;;=1^238.1
 ;;^UTILITY(U,$J,358.3,14490,1,8,0)
 ;;=8^Connective and Oth Soft Tissue
 ;;^UTILITY(U,$J,358.3,14490,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,14491,0)
 ;;=238.2^^87^787^17
 ;;^UTILITY(U,$J,358.3,14491,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14491,1,1,0)
 ;;=1^238.2
 ;;^UTILITY(U,$J,358.3,14491,1,8,0)
 ;;=8^Skin
 ;;^UTILITY(U,$J,358.3,14491,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,14492,0)
 ;;=238.3^^87^787^2
 ;;^UTILITY(U,$J,358.3,14492,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14492,1,1,0)
 ;;=1^238.3
 ;;^UTILITY(U,$J,358.3,14492,1,8,0)
 ;;=8^Breast
 ;;^UTILITY(U,$J,358.3,14492,2)
 ;;=^81956
 ;;^UTILITY(U,$J,358.3,14493,0)
 ;;=238.4^^87^787^15
 ;;^UTILITY(U,$J,358.3,14493,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14493,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,14493,1,8,0)
 ;;=8^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,14493,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,14494,0)
 ;;=238.5^^87^787^6
 ;;^UTILITY(U,$J,358.3,14494,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14494,1,1,0)
 ;;=1^238.5
 ;;^UTILITY(U,$J,358.3,14494,1,8,0)
 ;;=8^Histiocytic and Mast Cells
 ;;^UTILITY(U,$J,358.3,14494,2)
 ;;=^267778
 ;;^UTILITY(U,$J,358.3,14495,0)
 ;;=238.6^^87^787^14
 ;;^UTILITY(U,$J,358.3,14495,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14495,1,1,0)
 ;;=1^238.6
 ;;^UTILITY(U,$J,358.3,14495,1,8,0)
 ;;=8^Plasma Cells
 ;;^UTILITY(U,$J,358.3,14495,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,14496,0)
 ;;=238.71^^87^787^4
 ;;^UTILITY(U,$J,358.3,14496,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14496,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,14496,1,8,0)
 ;;=8^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,14496,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,14497,0)
 ;;=238.72^^87^787^7
 ;;^UTILITY(U,$J,358.3,14497,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14497,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,14497,1,8,0)
 ;;=8^Low Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,14497,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,14498,0)
 ;;=238.73^^87^787^5
 ;;^UTILITY(U,$J,358.3,14498,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14498,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,14498,1,8,0)
 ;;=8^High Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,14498,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,14499,0)
 ;;=238.74^^87^787^9
 ;;^UTILITY(U,$J,358.3,14499,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14499,1,1,0)
 ;;=1^238.74
 ;;^UTILITY(U,$J,358.3,14499,1,8,0)
 ;;=8^Myelody Synd w/ 5q Deletion
 ;;^UTILITY(U,$J,358.3,14499,2)
 ;;=^334030
 ;;^UTILITY(U,$J,358.3,14500,0)
 ;;=238.75^^87^787^10
 ;;^UTILITY(U,$J,358.3,14500,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14500,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,14500,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,14500,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,14501,0)
 ;;=238.76^^87^787^11
 ;;^UTILITY(U,$J,358.3,14501,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14501,1,1,0)
 ;;=1^238.76
 ;;^UTILITY(U,$J,358.3,14501,1,8,0)
 ;;=8^Myelofibrosis w/Myeloid Metaplasia
 ;;^UTILITY(U,$J,358.3,14501,2)
 ;;=^334032
 ;;^UTILITY(U,$J,358.3,14502,0)
 ;;=238.77^^87^787^16
 ;;^UTILITY(U,$J,358.3,14502,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14502,1,1,0)
 ;;=1^238.77
 ;;^UTILITY(U,$J,358.3,14502,1,8,0)
 ;;=8^Post Transp Lymphoprolif d/o PTLD
 ;;^UTILITY(U,$J,358.3,14502,2)
 ;;=^336526
 ;;^UTILITY(U,$J,358.3,14503,0)
 ;;=238.79^^87^787^12
 ;;^UTILITY(U,$J,358.3,14503,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14503,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,14503,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue
 ;;^UTILITY(U,$J,358.3,14503,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,14504,0)
 ;;=238.8^^87^787^13
 ;;^UTILITY(U,$J,358.3,14504,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14504,1,1,0)
 ;;=1^238.8
 ;;^UTILITY(U,$J,358.3,14504,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,14504,2)
 ;;=^267779
 ;;^UTILITY(U,$J,358.3,14505,0)
 ;;=238.9^^87^787^8
 ;;^UTILITY(U,$J,358.3,14505,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14505,1,1,0)
 ;;=1^238.9
 ;;^UTILITY(U,$J,358.3,14505,1,8,0)
 ;;=8^Lymph/Hematopoietic Tissue NOS
 ;;^UTILITY(U,$J,358.3,14505,2)
 ;;=^267780
 ;;^UTILITY(U,$J,358.3,14506,0)
 ;;=239.0^^87^788^5
 ;;^UTILITY(U,$J,358.3,14506,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14506,1,1,0)
 ;;=1^239.0
 ;;^UTILITY(U,$J,358.3,14506,1,8,0)
 ;;=8^Digestive Neoplasm NOS
